Bolar investor litigation
Executive Summary
Aug. 4 complaint by investor Martin Bergstein alleges firm violated federal securities laws and engaged in fraud and "other misrepresentations." The plaintiff seeks unspecified damages for himself "and all other persons who during the period Aug. 21, 1987 to Aug. 3, 1989 purchased" Bolar stock. In an Aug. 10 statement, firm said the complaint is based on "the alleged failure" to disclose that its ANDA for a generic version of Dyazide "was fraudulent and questionable." Bolar commented that the allegations "are without merit" and said it will "defend the action vigorously".